Literature DB >> 27914267

Intein-mediated site-specific synthesis of tumor-targeting protein delivery system: Turning PEG dilemma into prodrug-like feature.

Yingzhi Chen1, Meng Zhang1, Hongyue Jin2, Yisi Tang3, Huiyuan Wang2, Qin Xu3, Yaping Li2, Feng Li4, Yongzhuo Huang5.   

Abstract

Poor tumor-targeted and cytoplasmic delivery is a bottleneck for protein toxin-based cancer therapy. Ideally, a protein toxin drug should remain stealthy in circulation for prolonged half-life and reduced side toxicity, but turn activated at tumor. PEGylation is a solution to achieve the first goal, but creates a hurdle for the second because PEG rejects interaction between the drugs and tumor cells therein. Such PEG dilemma is an unsolved problem in protein delivery. Herein proposed is a concept of turning PEG dilemma into prodrug-like feature. A site-selectively PEGylated, gelatinase-triggered cell-penetrating trichosanthin protein delivery system is developed with three specific aims. The first is to develop an intein-based ligation method for achieving site-specific modification of protein toxins. The second is to develop a prodrug feature that renders protein toxins remaining stealthy in blood for reduced side toxicity and improved EPR effect. The third is to develop a gelatinase activatable cell-penetration strategy for enhanced tumor targeting and cytoplasmic delivery. Of note, site-specific modification is a big challenge in protein drug research, especially for such a complicated, multifunctional protein delivery system. We successfully develop a protocol for constructing a macromolecular prodrug system with intein-mediated ligation synthesis. With an on-column process of purification and intein-mediated cleavage, the site-specific PEGylation then can be readily achieved by conjugation with the activated C-terminus, thus constructing a PEG-capped, cell-penetrating trichosanthin system with a gelatinase-cleavable linker that enables tumor-specific activation of cytoplasmic delivery. It provides a promising method to address the PEG dilemma for enhanced protein drug delivery, and importantly, a facile protocol for site-specific modification of such a class of protein drugs for improving their druggability and industrial translation.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cell-penetrating peptide; Gelatinase; Intein-mediated protein ligation (IPL); Protein toxin; Site-specific PEGylation; Trichosanthin

Mesh:

Substances:

Year:  2016        PMID: 27914267      PMCID: PMC5527826          DOI: 10.1016/j.biomaterials.2016.11.033

Source DB:  PubMed          Journal:  Biomaterials        ISSN: 0142-9612            Impact factor:   12.479


  34 in total

1.  Conjugation of folate via gelonin carbohydrate residues retains ribosomal-inactivating properties of the toxin and permits targeting to folate receptor positive cells.

Authors:  S F Atkinson; T Bettinger; L W Seymour; J P Behr; C M Ward
Journal:  J Biol Chem       Date:  2001-05-18       Impact factor: 5.157

2.  Mapping the antigenic determinants and reducing the immunogenicity of trichosanthin by site-directed mutagenesis.

Authors:  Qunxing An; Sanhua Wei; Shijie Mu; Xianqing Zhang; Yingfeng Lei; Wei Zhang; Ning Jia; Xiaodong Cheng; Ailing Fan; Zhidong Li; Zhikai Xu
Journal:  J Biomed Sci       Date:  2006-09-15       Impact factor: 8.410

Review 3.  Issues related to targeted delivery of proteins and peptides.

Authors:  Yingjuan Lu; Jun Yang; Emanuela Sega
Journal:  AAPS J       Date:  2006-07-21       Impact factor: 4.009

Review 4.  Immunogenicity of protein therapeutics.

Authors:  Anne S De Groot; David W Scott
Journal:  Trends Immunol       Date:  2007-10-25       Impact factor: 16.687

5.  Intracellular re-localisation by photochemical internalisation enhances the cytotoxic effect of gelonin--quantitative studies in normal rat liver.

Authors:  Josephine Woodhams; Pei-Jen Lou; Pål K Selbo; Alexander Mosse; Dahmane Oukrif; Alexander MacRobert; Marco Novelli; Qian Peng; Kristian Berg; Stephen G Bown
Journal:  J Control Release       Date:  2009-11-22       Impact factor: 9.776

Review 6.  The low density lipoprotein receptor-related protein (LRP) 1 and its function in lung diseases.

Authors:  L Wujak; P Markart; M Wygrecka
Journal:  Histol Histopathol       Date:  2016-03-01       Impact factor: 2.303

7.  Reducing the immunogenicity and improving the in vivo activity of trichosanthin by site-directed pegylation.

Authors:  X H He; P C Shaw; S C Tam
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

8.  PTD-Modified ATTEMPTS for Enhanced Toxin-based Cancer Therapy: An In Vivo Proof-of-Concept Study.

Authors:  Meong Cheol Shin; Jian Zhang; Kyoung Ah Min; Huining He; Allan E David; Yongzhuo Huang; Victor C Yang
Journal:  Pharm Res       Date:  2015-02-21       Impact factor: 4.200

9.  Low-density lipoprotein receptor-related protein 1 is an essential receptor for trichosanthin in 2 choriocarcinoma cell lines.

Authors:  Yizu Jiao; Wangyi Liu
Journal:  Biochem Biophys Res Commun       Date:  2009-12-05       Impact factor: 3.575

10.  Novel prodrug-like fusion toxin with protease-sensitive bioorthogonal PEGylation for tumor targeting.

Authors:  Nikolas Stefan; Martina Zimmermann; Manuel Simon; Uwe Zangemeister-Wittke; Andreas Plückthun
Journal:  Bioconjug Chem       Date:  2014-11-14       Impact factor: 6.069

View more
  14 in total

Review 1.  Advances on Tumor-Targeting Delivery of Cytotoxic Proteins.

Authors:  Akmal M Asrorov; Zeyun Gu; Kyoung Ah Min; Meong Cheol Shin; Yongzhuo Huang
Journal:  ACS Pharmacol Transl Sci       Date:  2019-12-30

Review 2.  Toxic proteins application in cancer therapy.

Authors:  Zahra Setayesh-Mehr; Mahdiye Poorsargol
Journal:  Mol Biol Rep       Date:  2021-04-25       Impact factor: 2.316

3.  Glioma Dual-Targeting Nanohybrid Protein Toxin Constructed by Intein-Mediated Site-Specific Ligation for Multistage Booster Delivery.

Authors:  Yingzhi Chen; Meng Zhang; Hongyue Jin; Dongdong Li; Fan Xu; Aihua Wu; Jinyu Wang; Yongzhuo Huang
Journal:  Theranostics       Date:  2017-08-15       Impact factor: 11.556

Review 4.  Extracellular vesicles as a platform for membrane-associated therapeutic protein delivery.

Authors:  Yoosoo Yang; Yeonsun Hong; Eunji Cho; Gi Beom Kim; In-San Kim
Journal:  J Extracell Vesicles       Date:  2018-03-01

5.  Delivery of docetaxel using pH-sensitive liposomes based on D-α-tocopheryl poly(2-ethyl-2-oxazoline) succinate: Comparison with PEGylated liposomes.

Authors:  Shu Han; Ruiyang Sun; Hong Su; Jing Lv; Huan Xu; Di Zhang; Yuanshan Fu
Journal:  Asian J Pharm Sci       Date:  2018-09-18       Impact factor: 6.598

6.  Genetically-engineered "all-in-one" vaccine platform for cancer immunotherapy.

Authors:  Aihua Wu; Yingzhi Chen; Hairui Wang; Ya Chang; Meng Zhang; Pengfei Zhao; Yisi Tang; Qin Xu; Zhuangzhi Zhu; Yang Cao; Yongzhuo Huang
Journal:  Acta Pharm Sin B       Date:  2021-06-08       Impact factor: 11.413

7.  Nanoparticles for co-delivery of osimertinib and selumetinib to overcome osimertinib-acquired resistance in non-small cell lung cancer.

Authors:  Wu Chen; Danlei Yu; Shi-Yong Sun; Feng Li
Journal:  Acta Biomater       Date:  2021-05-25       Impact factor: 10.633

Review 8.  Heparin-Regulated Prodrug-Type Macromolecular Theranostic Systems for Cancer Therapy.

Authors:  Huiyuan Wang; Cheol Moon; Meong Cheol Shin; Yaping Wang; Huining He; Victor C Yang; Yongzhuo Huang
Journal:  Nanotheranostics       Date:  2017-03-03

9.  Nanotechnology-based combination therapy for overcoming multidrug-resistant cancer.

Authors:  Meng Zhang; Ergang Liu; Yanna Cui; Yongzhuo Huang
Journal:  Cancer Biol Med       Date:  2017-08       Impact factor: 4.248

10.  On-demand PEGylation and dePEGylation of PLA-based nanocarriers via amphiphilic mPEG-TK-Ce6 for nanoenabled cancer chemotherapy.

Authors:  Yueqiang Zhu; Chao Chen; Ziyang Cao; Song Shen; Laisheng Li; Dongdong Li; Junxia Wang; Xianzhu Yang
Journal:  Theranostics       Date:  2019-10-22       Impact factor: 11.556

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.